HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system.

AbstractPURPOSE:
The purpose of this study was to determine whether the inactivated hemagglutinating virus of Japan (HVJ)-liposome method can induce phosphorothioate oligonucleotides effectively into an experimentally-induced choroidal neovascularization of rats. We also examined whether antisense phosphorothioate oligonucleotides against VEGF could be induced into choroidal neovascularization as a therapeutic agent by the HVJ-liposome method.
METHODS:
The experiments were conducted on a rat model of choroidal neovascularization. FITC-labeled phosphorothioate oligonucleotides were coencapsulated in liposomes. The liposomes were coated with the envelope of inactivated HVJ and injected into the vitreous cavity following photocoagulation of pigmented rat eyes. The eyes were removed following injection, fixed, frozen and cut into thin sections. Induction of oligonucleotides was observed under a laser confocal scanning microscope for fluorescence and the development of choroidal neovascularization was evaluated histopathologically.
RESULTS:
Phosphorothioate oligonucleotides were effectively induced into ganglion cells and into the cells of the choroidal neovascularization induced by laser photocoagulation. Highly effective induction of oligos was observed 3 to 14 days after intravitreal injection of HVJ-liposomes after which the level decreased. Antisense oligonucleotides against VEGF were induced specifically into cells in the choroidal neovascularization, however neovascularization was still observed.
CONCLUSIONS:
Phosphorothioate oligonucleotides can be effectively induced into ganglion cells, and specifically into cells in choroidal neovascularization. Although antisense oligonucleotides against VEGF failed to prevent choroidal neovascularization, the HVJ-liposome method provided a highly effective means of inducing antisense oligos for in vivo antisense therapy.
AuthorsN Ogata, T Otsuji, M Matsushima, T Kimoto, R Yamanaka, K Takahashi, M Wada, M Uyama, Y Kaneda
JournalCurrent eye research (Curr Eye Res) Vol. 18 Issue 4 Pg. 261-9 (Apr 1999) ISSN: 0271-3683 [Print] England
PMID10372985 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Drug Carriers
  • Endothelial Growth Factors
  • Fluorescent Dyes
  • Liposomes
  • Lymphokines
  • Oligonucleotides, Antisense
  • Thionucleotides
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Fluorescein-5-isothiocyanate
Topics
  • Animals
  • Choroid (blood supply)
  • Drug Carriers
  • Endothelial Growth Factors (genetics)
  • Fluorescein-5-isothiocyanate
  • Fluorescent Dyes
  • Gene Transfer Techniques
  • Genetic Vectors
  • Liposomes
  • Lymphokines (genetics)
  • Neovascularization, Pathologic (pathology)
  • Oligonucleotides, Antisense (administration & dosage, pharmacology)
  • Rats
  • Rats, Inbred BN
  • Respirovirus (genetics)
  • Thionucleotides (genetics)
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: